Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cholecalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CDC25A | P30304 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholecalciferol SCHEMBL8082779 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL13475366 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL4545272 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL2734123 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL13717177 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL23878716 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL13989117 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL21264875 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL20511118 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Cholecalciferol SCHEMBL15695 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | VDR 1913/4885MEN1 1005/4885KMT2A 3672/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | VDR 3807/4885MEN1 3488/4885KMT2A 4543/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | VDR 3807/4885MEN1 3488/4885KMT2A 4543/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | VDR 2066/4885MEN1 3419/4885KMT2A 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.